Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) is dated May 22, 2024. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on stock listing compliance.
Material Changes
The material event reported is the failure of the company's common stock to maintain a minimum bid price of $1.00 per share for 30 consecutive business days between April 10, 2024, and May 21, 2024. This deficiency violates Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-day compliance period ending November 18, 2024, to regain compliance.
- Requirements: To comply, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to the compliance date.
- Contingencies: If the company fails to regain compliance by November 18, 2024, it may be eligible for an additional 180-day period. This would require transferring its listing to the Nasdaq Capital Market and meeting other listing standards, potentially via a reverse stock split.
- Risks: There is no assurance the company will regain compliance or that an appeal of a potential delisting determination would be successful. Immediate delisting is not occurring, but the risk of future delisting exists if the deficiency is not cured.
Investor Verification Checklist
- Monitor the daily closing bid price of GOSS stock to track progress toward the $1.00 threshold.
- Watch for announcements regarding a potential reverse stock split or transfer to the Nasdaq Capital Market.
- Verify the company's cash position in subsequent filings (10-Q/10-K) to assess its ability to fund operations while addressing listing issues.
- Check for any further correspondence from Nasdaq regarding the company's ability to cure the deficiency.